Actinogen Medical (ASX:ACW) has announced that one of its clinical advisory board members, Professor Jeffrey Cummings, has been awarded a Lifetime Achievement Award from the American Alzheimer’s Association.
The award was announced at the recent Alzheimer’s Association International Conference (AAIC) 2018 in Chicago.
It is presented to honour individuals who have made a significant scientific contribution and lifetime commitment to progress the fight against Alzheimer’s disease and dementia.
Professor Cummings is a founding member of Actinogen’s clinical advisory board and continues to provide advice and research expertise to the company in the development for Xanamem.
Professor Cummings founded the Cleveland Clinic Lou Ruvo Centre for Brain Health in Las Vegas, Nevada and Cleveland, Ohio.
He is currently the Principal Investigator and Director of the NIH/NIGMS-funded Centre for Neurodegeneration and Translational Neuroscience and the founding director of the UCLA Alzheimer’s Disease Research Centre.
According to CEO of Actinogen Medical, Dr Bill Ketelbey, “Having one of our Advisory Board members receive such a prestigious award reflects the exceptional calibre of internationally recognised academic experts supporting Actinogen’s development of Xanamem.
"Jeff is a renowned Alzheimer’s researcher and has devoted much of his life to researching and developing treatments to fight against this devastating disease. No one deserves this award more than Jeff and we’re delighted to have his intellect and research expertise to advise on the development of Xanamem.”